NasdaqGM - Nasdaq Real Time Price USD
TScan Therapeutics, Inc. (TCRX)
1.2150
-0.0250
(-2.02%)
As of 12:59:36 PM EDT. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 7 | 6 |
| Avg. Estimate | -0.32 | -0.33 | -1.23 | -1.16 |
| Low Estimate | -0.58 | -0.57 | -2.13 | -1.73 |
| High Estimate | -0.22 | -0.22 | -0.85 | -0.78 |
| Year Ago EPS | -0.28 | -0.25 | -1.14 | -1.23 |
Revenue Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 6 |
| Avg. Estimate | 1.3M | 1.3M | 5.88M | 7.94M |
| Low Estimate | 500k | 500k | 3.7M | -- |
| High Estimate | 2.5M | 2.5M | 9.67M | 20.39M |
| Year Ago Sales | 536k | 1.05M | 2.82M | 5.88M |
| Sales Growth (year/est) | 143.47% | 24.40% | 108.72% | 35.08% |
Earnings History
| Currency in USD | 6/30/2024 | 9/30/2024 | 12/31/2024 | 3/31/2025 |
|---|---|---|---|---|
| EPS Est. | -0.28 | -0.29 | -0.28 | -0.31 |
| EPS Actual | -0.28 | -0.25 | -0.29 | -0.26 |
| Difference | 0 | 0.04 | -0.01 | 0.05 |
| Surprise % | 1.35% | 14.32% | -5.38% | 15.03% |
EPS Trend
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -0.32 | -0.33 | -1.23 | -1.16 |
| 7 Days Ago | -0.27 | -0.28 | -1.09 | -1.05 |
| 30 Days Ago | -0.28 | -0.29 | -1.13 | -1.1 |
| 60 Days Ago | -0.28 | -0.29 | -1.13 | -1.1 |
| 90 Days Ago | -0.3 | -0.3 | -1.22 | -1.3 |
EPS Revisions
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | 2 | 2 | -- | -- |
| Up Last 30 Days | 2 | 2 | 3 | 3 |
| Down Last 7 Days | 1 | 1 | -- | -- |
| Down Last 30 Days | 1 | 1 | 2 | 2 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| TCRX | -15.42% | -30.07% | -8.31% | 5.89% |
| S&P 500 | 13.32% | 2.69% | 7.77% | 13.75% |
Upgrades & Downgrades
| Maintains | HC Wainwright & Co.: Buy to Buy | 5/7/2025 |
| Reiterates | Needham: Buy to Buy | 4/8/2025 |
| Maintains | Barclays: Overweight to Overweight | 3/7/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/6/2025 |
| Maintains | Needham: Buy to Buy | 3/5/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 12/11/2024 |
Related Tickers
SYRE Spyre Therapeutics, Inc.
15.07
+1.28%
TRDA Entrada Therapeutics, Inc.
8.14
+1.62%
ERAS Erasca, Inc.
1.2450
+1.22%
ORKA Oruka Therapeutics, Inc.
10.44
+1.26%
REPL Replimune Group, Inc.
8.86
+8.05%
RCUS Arcus Biosciences, Inc.
8.84
+1.49%
KYMR Kymera Therapeutics, Inc.
30.30
+0.33%
CGEM Cullinan Therapeutics, Inc.
7.76
+0.65%
ORIC ORIC Pharmaceuticals, Inc.
5.42
+5.35%
TYRA Tyra Biosciences, Inc.
9.94
+2.69%